Log In
BCIQ
Print this Print this
 

fevipiprant (QAW039)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionProstaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2; CRTH2; GPR44; DP2; CD294) antagonist
Molecular Target Prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2) (CRTH2) (GPR44) (DP2) (CD294)
Mechanism of ActionProstaglandin D2 (PGD2) receptor subtype DP2 (CRTH2) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today